Evidence map›Paper›PMID 41989176›Full record

ArticleMicrobiology spectrum2026

Development of a stable low-copy mini F plasmid derivative for evaluating β-lactamase substrate specificity through antimicrobial susceptibility testing.

Haruka Nakagawa Kamura, Kotaro Aoki, Kohji Komori, Kazuhiro Tateda, Yoshikazu Ishii

Abstract read
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haruka Nakagawa Kamura *Center for the Planetary Health and Innovation Science (PHIS), Hiroshima University, The IDEC Institute, Higashi-Hiroshima, Japan.
Kotaro Aoki *Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan.ORCID 0000-0002-9237-1217
Kohji KomoriDivision of Collaborative Regional Infection Control, Department of Community Well-being, Toho University School of Medicine, Tokyo, Japan.
Kazuhiro TatedaDepartment of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan.
Yoshikazu IshiiCenter for the Planetary Health and Innovation Science (PHIS), Hiroshima University, The IDEC Institute, Higashi-Hiroshima, Japan.ORCID 0000-0002-1943-4648

Funding

Japan Society for the Promotion of Science JP21K08497The project Research Grant of Toho University School of Medicine 23-3
6 · The paper itself

Abstract

Traditionally, the impact of the substrate specificity of β-lactamase produced by bacteria on β-lactam resistance (β-lactamase-mediated resistance) has been assessed by performing antimicrobial susceptibility testing (AST) on transformants carrying the cloned gene on arbitrarily chosen β-lactamase-free plasmid vectors. However, because the promoter strength and plasmid copy number of these vectors are not standardized, the resulting β-lactamase expression levels vary, further hampering cross-study comparisons. We constructed pMiniF-1 by inserting a

Indexed as

Anti-Bacterial Agentsbeta-LactamasesEscherichia coliPlasmidsBacterial Proteinsbeta-Lactam ResistanceMicrobial Sensitivity TestsSubstrate SpecificityAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasesantimicrobial susceptibility testingmini F plasmid derivativeβ-lactamaseβ-lactamase substrate specificity

Identifiers

PMID41989176
PMCPMC13228080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.